Benitec Biopharma Inc. (BNTC)
$9.07+2.25%Close
SELLCRISIS · day 20
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $312M
- Beta
- 0.25
- P/E (TTM)
- -9.18
- Short % float
- 6.09%
- Days to cover
- 10.2
- SI change
- -6.7%
- 1W
- -1.73%
- 1M
- -25.59%
- vs SPY 1W
- -2.16%
- vs SPY 1M
- -27.66%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 0
- GROWTH
- 51
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-17.0%
REV YoY-
ROE-7.2%
EPS YoY-
ROA-24.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-9.18
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B2.37
P/FCF-
EV/EBITDA-2.56
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.43
ALTMAN Z-
CURR RATIO34.00
ND/EBITDA-
BETA0.25
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on BNTC?
- LOPJLB’s latest quantitative signal on Benitec Biopharma Inc. (BNTC) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BNTC in?
- Benitec Biopharma Inc. (BNTC) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Benitec Biopharma Inc. (BNTC) do?
- Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single…